144 related articles for article (PubMed ID: 20873795)
21. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
22. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
Wen WH; Wang SY; Tsai KC; Cheng YS; Yang AS; Fang JM; Wong CH
Bioorg Med Chem; 2010 Jun; 18(11):4074-84. PubMed ID: 20452227
[TBL] [Abstract][Full Text] [Related]
23. GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains.
Kati WM; Saldivar AS; Mohamadi F; Sham HL; Laver WG; Kohlbrenner WE
Biochem Biophys Res Commun; 1998 Mar; 244(2):408-13. PubMed ID: 9514938
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
Ai W; Zhang J; Zalloum WA; Jia R; Cherukupalli S; Ding X; Sun Z; Sun L; Jiang X; Ma X; Li Z; Wang D; Huang B; Zhan P; Liu X
Eur J Med Chem; 2020 Apr; 191():112147. PubMed ID: 32092589
[TBL] [Abstract][Full Text] [Related]
25. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
Park JW; Jo WH
J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
[TBL] [Abstract][Full Text] [Related]
26. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
27. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
Abed Y; Nehmé B; Baz M; Boivin G
Antiviral Res; 2008 Feb; 77(2):163-6. PubMed ID: 17919743
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and evaluation of carboxyl-modified oseltamivir derivatives with improved lipophilicity as neuraminidase inhibitors.
Wang B; Wang K; Meng P; Hu Y; Yang F; Liu K; Lei Z; Chen B; Tian Y
Bioorg Med Chem Lett; 2018 Nov; 28(21):3477-3482. PubMed ID: 30266543
[TBL] [Abstract][Full Text] [Related]
29. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Magano J
Chem Rev; 2009 Sep; 109(9):4398-438. PubMed ID: 19537777
[No Abstract] [Full Text] [Related]
30. Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives.
Chand P; Babu YS; Bantia S; Rowland S; Dehghani A; Kotian PL; Hutchison TL; Ali S; Brouillette W; El-Kattan Y; Lin TH
J Med Chem; 2004 Apr; 47(8):1919-29. PubMed ID: 15055992
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Gubareva LV
Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
[TBL] [Abstract][Full Text] [Related]
32. On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9.
Aruksakunwong O; Malaisree M; Decha P; Sompornpisut P; Parasuk V; Pianwanit S; Hannongbua S
Biophys J; 2007 Feb; 92(3):798-807. PubMed ID: 17085491
[TBL] [Abstract][Full Text] [Related]
33. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site.
Finley JB; Atigadda VR; Duarte F; Zhao JJ; Brouillette WJ; Air GM; Luo M
J Mol Biol; 1999 Nov; 293(5):1107-19. PubMed ID: 10547289
[TBL] [Abstract][Full Text] [Related]
34. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
[TBL] [Abstract][Full Text] [Related]
35. Galactose-conjugates of the oseltamivir pharmacophore--new tools for the characterization of influenza virus neuraminidases.
Carbain B; Martin SR; Collins PJ; Hitchcock PB; Streicher H
Org Biomol Chem; 2009 Jun; 7(12):2570-5. PubMed ID: 19503932
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.
Ju H; Xiu S; Ding X; Shang M; Jia R; Huang B; Zhan P; Liu X
Eur J Med Chem; 2020 Feb; 187():111940. PubMed ID: 31835169
[TBL] [Abstract][Full Text] [Related]
37. Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus.
Wang SQ; Cheng XC; Dong WL; Wang RL; Chou KC
Biochem Biophys Res Commun; 2010 Oct; 401(2):188-91. PubMed ID: 20849817
[TBL] [Abstract][Full Text] [Related]
38. Influenza virus susceptibility and resistance to oseltamivir.
Aoki FY; Boivin G; Roberts N
Antivir Ther; 2007; 12(4 Pt B):603-16. PubMed ID: 17944268
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and Biological Evaluation of
Hu Y; Chen B; Lei Z; Zhao H; Zhu H; Quan P; Tian Y
Molecules; 2019 Jun; 24(11):. PubMed ID: 31185617
[TBL] [Abstract][Full Text] [Related]
40. Search for novel neuraminidase inhibitors: Design, synthesis and interaction of oseltamivir derivatives with model membrane using docking, NMR and DSC methods.
D'Souza C; Kanyalkar M; Joshi M; Coutinho E; Srivastava S
Biochim Biophys Acta; 2009 Sep; 1788(9):1740-51. PubMed ID: 19397892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
